☆ 4.7 Article

Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs

CLINICAL INFECTIOUS DISEASES (2023)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Molnupiravir: A new candidate for COVID-19 treatment

Fariba Pourkarim et al.

Summary: This review summarizes the published literature on the mechanism of action, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID-19 patients.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2022)

添加到收藏夹

Article Multidisciplinary Sciences

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen et al.

Summary: PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor, has been discovered with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. This new drug has shown promise in countering the threat of COVID-19 with its oral activity and safety in clinical trials.

SCIENCE (2021)

添加到收藏夹

Article Immunology

Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic

J. Ryan Bariola et al.

Summary: The emergency authorized COVID-19-neutralizing monoclonal antibodies can benefit outpatients with mild to moderate COVID-19 infections, but there are reported barriers to distribution and uptake. The authors present their distribution model in a large health system and share early lessons learned.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹

Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs

相关参考文献

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Molnupiravir: A new candidate for COVID-19 treatment

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic

导出引文

分享论文